Literature DB >> 3309004

Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term captopril therapy in heart failure.

D M Mancini1, L Davis, J P Wexler, B Chadwick, T H LeJemtel.   

Abstract

Maximal oxygen uptake (VO2), skeletal muscle blood flow by xenon-133 washout technique and femoral vein arteriovenous oxygen difference and lactate were measured at rest and during maximal bicycle exercise in eight patients with severe congestive heart failure before and after 8 weeks of therapy with captopril. During therapy, skeletal muscle blood flow at rest increased significantly from 1.5 +/- 0.6 to 2.6 +/- 1.0 ml/100 g per min (p less than 0.05), with a concomitant decrease in the femoral arteriovenous oxygen difference from 10.0 +/- 1.7 to 8.3 +/- 1.9 ml/100 ml (p less than 0.05). Maximal VO2 increased significantly from 13.4 +/- 3.0 to 15.5 +/- 4.1 ml/kg per min (p less than 0.05). In four patients, the increase in maximal VO2 averaged 3.7 ml/kg per min (range 2.7 to 4.9), whereas in the remaining four patients, it was less than 1 ml/kg per min. Overall, peak skeletal muscle blood flow attained during exercise did not change significantly during long-term therapy with captopril (19.6 +/- 6.2 versus 27.6 +/- 14.3 ml/100 g per min, p = NS). However, the four patients with a significant increase in maximal VO2 experienced substantial increases in peak skeletal muscle blood flow and the latter changes were linearly correlated with changes in maximal VO2 (r = 0.95, p less than 0.001). Femoral arteriovenous oxygen difference at peak exercise was unchanged (12.6 +/- 2.6 versus 12.6 +/- 2.4 ml/100 ml). Thus, improvement in maximal VO2 produced by long-term therapy with captopril is associated with an increased peripheral vasodilatory response to exercise, and this improvement only occurs when the peak blood flow is augmented.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3309004     DOI: 10.1016/s0735-1097(87)80279-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

Review 1.  Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure.

Authors:  Stuart D Katz; Haoyi Zheng
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

2.  Management of heart failure.

Authors:  T H Le Jemtel
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 2.931

Review 3.  Vascular tone in heart failure: the neuroendocrine-therapeutic interface.

Authors:  J G Cleland; C M Oakley
Journal:  Br Heart J       Date:  1991-10

Review 4.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 5.  ACE inhibitors in acute and chronic ischaemia: current status and future promise.

Authors:  E H Sonnenblick; M Zhao; C Eng; T H LeJemtel; S M Factor; J Capasso; P Anversa
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

6.  ACE genotype may have an effect on single versus multiple set preferences in strength training.

Authors:  Muzaffer Colakoglu; F Sirri Cam; Bulent Kayitken; Firat Cetinoz; Sule Colakoglu; Mustafa Turkmen; Metin Sayin
Journal:  Eur J Appl Physiol       Date:  2005-07-08       Impact factor: 3.078

Review 7.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 8.  Peripheral factors in the management of congestive heart failure.

Authors:  L Demopoulos; T H LeJemtel
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

Review 9.  Angiotensin converting enzyme inhibitors versus digoxin for the treatment of congestive heart failure.

Authors:  I Crozier; H Ikram
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 10.  Cellular and molecular pathobiology of heart failure with preserved ejection fraction.

Authors:  Sumita Mishra; David A Kass
Journal:  Nat Rev Cardiol       Date:  2021-01-11       Impact factor: 49.421

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.